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Introduction
An estimated 130–150 million people live with hepatitis C virus (HCV) [1]. A significant num-
ber of people with HCV will progress to chronic disease, hepatocellular carcinoma, and death
[2]. Approximately 80 million people live with chronic HCV infection, and in 2013 an estimat-
ed 700,000 people died from HCV [3,4]. More than 80% of the HCV burden is in low- and
middle-income countries [5]. Since there is no vaccine for HCV, prevention strategies currently
rely on limiting exposure to the virus. The six different HCV genotypes vary geographically
and affect susceptibility to some treatment regimens [6]. Recently, there have been significant
scientific advances for treatment of HCV that have led to substantial interest in delivering
HCV services through national programmes [7].
Summary Points
• New oral short-duration regimens using direct-acting antiviral medicines for hepatitis
C virus (HCV) have the potential to facilitate treatment and improve outcomes.
• Translating scientific advances into reduced disease burden requires well-designed
programmes encompassing prevention, screening, treatment, and
strategic information.
• Engagement from countries, civil society, donors, and policymakers is needed to gener-
ate political commitment, mobilise resources, and reduce diagnostic and medicine
costs for HCV.
• Countries should estimate the resources required to implement planned HCV preven-
tion, screening, and treatment strategies and their expected health, societal, and finan-
cial benefits to mobilise domestic and international funding.
• Countries could integrate HCV prevention, screening, treatment, and strategic infor-
mation into HIV/AIDS programmes for financial, infrastructural, and health
workforce efficiencies.
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The first generation of direct-acting antivirals (DAAs) can cure specific genotypes when
combined with interferon and ribavirin for 6–12 months [8–10]. Unfortunately, genotyping is
unavailable at lower tiers of most health systems, interferon and ribavirin are difficult to toler-
ate, and interferon is an injectable medicine that requires administration by health care staff
and a cold supply chain for national distribution. Treatment with some second-generation
DAAs is associated with high rates of sustained virological response across genotypes and does
not require interferon and ribavirin [8–10]. Patient adherence is likely to be high with second-
generation DAAs because they are taken orally, are well-tolerated, and can be administered
through fixed-dose combinations. Moreover, they can potentially be decentralised to peripher-
al health facilities with non-specialised physicians and nurses because of simple prescribing
patterns, a short 3-month treatment course, and limited laboratory requirements.
There is an opportunity to translate scientific advances into effective public health program-
ming; however, significant challenges remain. For example, unlicensed health technologies
may perform poorly and thus waste scarce financial resources. Inappropriate use of drugs
could lead to population-level resistance and reduce treatment options. Failing to implement a
robust prevention strategy may lead to high levels of ongoing transmission. Finally, relying on
patients to pay for HCV treatment out-of-pocket could induce inequities in which poor and
marginalised populations cannot access essential HCV medicines.
Programme Development
The goal of viral hepatitis programming should be to decrease hepatitis-related morbidity,
mortality, and transmission. Such efforts require global, regional, and national stakeholders to
develop high-level political commitment, mobilise resources, and propose targets [11]. Since
many countries lack the necessary funding to provide HCV-related services, global stakehold-
ers could further ensure that new treatment regimens are affordable for low- and middle-
income countries. For example, some stakeholders aim to reduce HCV medicine costs through
market shaping, advocacy, and patent opposition [12–16]. The Global Fund for AIDS, Tuber-
culosis and Malaria (GFATM), the President’s Emergency Plan for AIDS Relief (PEPFAR),
and the President’s Malaria Initiative have been paramount in reducing HIV-, tuberculosis-,
and malaria-related mortality globally. While limited provisions by the GFATM to finance
HCV/HIV-co-infection screening and treatment in selected countries are encouraging, thus far
there has not been a global financing initiative to reduce the burden of HCV in low- and mid-
dle-income countries [17].
An important first step to mobilise support for a global financing initiative is the develop-
ment of an investment case [18]. This would communicate to donors that viral hepatitis is a
global epidemic that requires the same attention and resources as other major communicable
diseases (Fig. 1). To facilitate discussions with national development partners, countries should
estimate the financial, human, and physical resources required to implement planned HCV
prevention, screening, and treatment strategies and their expected benefits on population
health, society, and the economy. This information will help ministries of health explore exter-
nal and domestic sources of funding, such as national and local budgets, national health insur-
ance, and household out-of-pocket payments. Given the need to fund multiple public health
needs, countries should conduct studies to determine the optimal resource allocation across
diseases to improve the health and overall development of their populations.
There are ongoing efforts to increase the absolute number of skilled and motivated health
workers [19]. While these long-term strategies begin to improve the human resource crisis,
countries with current absolute health care worker shortages may need to consider task sharing
—with training and supervision—to community- and peripheral-based health workers in
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order to expand access to HCV screening and treatment, respectively. It is important for coun-
tries to also examine opportunities for programmatic synergies. Specifically, rather than creat-
ing a separate programme for viral hepatitis, an integrated programme for HIV/AIDS and viral
hepatitis could provide financial, infrastructural, and health workforce efficiencies. For exam-
ple, the HIV laboratory infrastructure could diagnose and monitor HCV; preventing HIV
through safe blood, harm reduction, and infection control also prevents HCV; HIV surveil-
lance systems could generate essential HCV data; increasing domestic antiretroviral production
capacity could improve access to HCV medicines and the HIV/AIDS workforce and health fa-
cilities can deliver essential HCV services. This approach would lead to integrated health pro-
gramming and services [20–22].
Prevention
HCV is transmitted through bodily fluids (e.g., blood, genital secretions, and cerebrospinal,
amniotic, peritoneal, or pleural fluids). HIV co-infection may increase HCV viraemia and
therefore increase the risk of transmission [23,24]. In contrast to hepatitis B, there is no vaccine
for HCV, and its identification is a research priority. Effective prevention of HCV may there-
fore depend on reducing exposure to the virus through successful implementation of preven-
tion interventions tailored to local transmission dynamics and expanded access to curative
treatment, which reduces the amount of circulating virus in the community.
In many low- and middle-income countries, it appears that health care–related exposures,
such as blood transfusion and percutaneous needlesticks, as well as injecting drug use are the
most important modes of HCV transmission [25–29]. To prevent transmission through blood
transfusion, blood and blood products must be universally screened [30]. Countries must screen
for HCV antibodies, should screen for HCV antibody and antigen when combination antibody-
antigen assays are available, and can screen for HCV RNA depending on available finances, labo-
ratory infrastructure, and HCV incidence in donors [30]. Preventing percutaneous transmission
in health care settings requires reducing unnecessary injections and implementing infection con-
trol measures, including exclusive use of therapeutic syringes with features to prevent reuse and
injuries as well as safe handling and disposal of sharps and waste [31]. Legislation mandating
Fig 1. Number of deaths due to major communicable diseases in 2013 [4]. Viral hepatitis deaths include
those related to acute viral hepatitis, liver cancer secondary to hepatitis B and hepatitis C, and cirrhosis of the
liver secondary to hepatitis B and hepatitis C.
doi:10.1371/journal.pmed.1001795.g001
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these measures may improve implementation in both public and private health care facilities
[32]. Expansion of harm reduction, including needle and syringe programmes and opiate substi-
tution therapy, is needed to reduce HCV risk among people who inject drugs (PWID) [33].
Mother-to-child HCV transmission is approximately 6% in women without HIV and 11%
in women with HIV [23]. There are currently no interventions to reduce HCV risk through
this mode of transmission. There is an urgent need to evaluate the safety and effectiveness of
DAAs during pregnancy and labour as they could reduce the concentration of virus in the
mother and reduce transmission risk [34]. Although there is limited evidence of heterosexual
HCV transmission [35], emerging data suggest potential for HCV transmission in men who
have sex with men (particularly in the context of HIV co-infection) [24]. Condoms can be used
to decrease sexual transmission risk. Finally, health education and training can help reduce
transmission during nonmedical (e.g., commercial barbering, body piercing, tattoos, and tradi-
tional circumcision) and occupational (e.g., health care and sanitation worker) exposures.
Increasing coverage of treatment has reduced the incidence of tuberculosis and HIV in
some settings [36,37]. Based on the simple principle of people being noninfectiousness after
they are cured, there is potential for rapid expansion of DAAs to decrease population transmis-
sion of HCV [38]. Importantly, studies in generalised (i.e., national prevalence1%) and con-
centrated (i.e., national prevalence<1% and prevalence in specific populations5%) HCV
epidemics indicate that DAA expansion in combination with other prevention interventions,
which include universal access to safe blood, infection control, and harm reduction, yields the
largest reduction in disease burden [39,40].
Screening
Diagnosing hepatitis C requires serologic testing for HCV antibodies. An accurate, thermosta-
ble, and affordable rapid test is needed to improve access to HCV screening in health and com-
munity systems for all people with HCV, including those co-infected with HIV [41]. Since
some of those initially infected will spontaneously clear the infection, nucleic acid amplification
of RNA is needed to confirm chronic HCV infection. In settings where laboratories are used
for HCV antibody screening, reflex HCV RNA testing after antibody is detected can ensure
prompt HCV RNA results for patients and providers [42]. HCV core antigen may be an alter-
native to HCV RNA for screening in some settings [43]. Valid algorithms need to be developed
to guide use of HCV biomarkers to diagnose HCV in different epidemiological contexts.
Many low- and middle-income countries have low diagnosis rates, and the majority of those
infected remain undiagnosed until they develop serious liver disease [44]. Expanded HCV test-
ing could achieve early diagnosis, but this has to be linked to care in order to reduce
HCV-related morbidity, mortality, and transmission. Given the limited resources available for
population screening efforts, epidemiological data should guide who should be prioritised for
testing. For example, in the United States, where there is a concentrated HCV epidemic, sub-
stantial effort is needed to screen people who may have been exposed to unsafe blood (i.e., peo-
ple born from 1945–1965, whose HCV prevalence is approximately 5-fold larger than other
birth cohorts, and people who have haemophilia) and key populations (i.e., people at high
HCV risk due to specific behaviours, such as PWID, sex workers, men who have sex with men,
and people in prisons and other closed settings of detention) [45,46]. HCV testing services
could reach the 1945–1965 birth cohort through systematic screening using birth dates in
health care facilities, while risk-based screening in health care facilities and mobile testing
could reach key populations. Key populations may also benefit from simultaneous screening of
other diseases which share common transmission routes, e.g. HIV and hepatitis B. In Egypt,
where there is a generalised HCV epidemic and HCV prevalence is highest in people with
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ongoing or a past history of medical injections, screening is provided in hospitals, all health fa-
cilities, workplaces, and using mobile testing [47,48]. Given the dramatic need to increase
knowledge of HCV status in most settings, community health workers may need to be trained
to provide counselling and rapid serologic tests, while nonspecialised physicians and nurses
may need to be trained on interpreting HCV RNA or core antigen results for diagnosing
chronic HCV infection.
Encouraging people to discover their HCV status and reduce transmission can be done
through targeted use of media, educational campaigns, World Hepatitis Day, and other
approaches. WHO’s 5C’s human rights approach for HIV screening may provide important
guiding principles for HCV screening (requiring informed Consent, Confidential in nature,
pre- and post-test Counselling, Correct test results, and Connections to care) [49]. Counselling
may focus on how to reduce the risk of acquiring or transmitting HCV, the need for repeat test-
ing (for key populations at high risk of acquiring HCV), and the possible benefits of therapy,
among other key messages.
Treatment
All people with confirmed chronic HCV infection should be offered high-quality care as soon
as possible. In addition to essential elements of primary care, this should also include screening
and management of alcohol use to prevent progression to cirrhosis [50]. Countries will also
need to decide when to start HCV treatment. Modelling suggests that treatment early in the
course of HCV disease for all or specific populations could prevent disease progression and on-
ward transmission [39,40,51]. However, not all people with chronic HCV infection will prog-
ress to fibrosis [2]. Moreover, transmission has been documented among people recently cured
who lacked access to prevention services [52]. Research is needed to determine cost-effective el-
igibility criteria for both key and other populations that maximise reductions in HCV-related
morbidity, mortality, and transmission in different epidemiological contexts.
Recent WHO guidelines recommend prioritising treatment among people with advanced fi-
brosis or cirrhosis in order to prevent liver cancer and death [53]. HCV has been shown to in-
crease mortality in people with HIV, while HIV has been shown to accelerate HCV disease
progression [54,55]. Therefore, people with HIV/HCV coinfection may also warrant treatment
prioritisation. The METAVIR system can be used to estimate the stage of HCV disease through
liver biopsy and identify individuals needing treatment [56]; however, liver biopsy is expensive,
subject to sampling errors, invasive for patients, and can lead to complications such as infec-
tions, excessive bleeding, pain, or accidental injury to other organs. Alternative non-invasive
staging criteria that use liver function tests and platelet counts to determine the degree of liver
fibrosis, such as the aminotransferase-to-platelet ratio index (APRI) and the Fibrosis-4 score
(FIB-4), may be a more useful approach for gauging treatment eligibility across different tiers
of health systems [57]. Systems should be put in place to retain and monitor people who do not
initiate treatment immediately.
Countries will also need to have a careful discussion on what drugs should be used to treat
HCV. Global and national guidelines can help ensure the rational selection of medicines in na-
tional essential medicine lists and health insurance. The regimen should, at a minimum, be
highly effective, well-tolerated, short-duration, and affordable (Table 1). Pangenotypic regi-
mens, i.e., regimens with similar efficacy across genotypes, eliminate the need for relatively ex-
pensive and inaccessible genotyping. For training, financial, and supply chain reasons, a single
regimen should be used for all populations (including paediatrics, pregnant women, and key
populations such as PWID). Evaluating the safety and effectiveness in these populations is a re-
search priority, since these populations have been systematically excluded from most clinical
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trials of new DAAs. Current WHO guidelines recommend sofosbuvir and ribavirin, with or
without pegylated interferon, as the preferred regimen for HCV treatment [53]. Major toxici-
ties with ribavirin, such as anaemia and foetal abnormalities, may indicate a need to consider
alternative regimens as they become available. Routine public health programming activities
should measure the incidence of these and other life-threatening adverse events [58].
Legal and financial barriers impose a significant obstacle in licensing and providing DAAs
in low- and middle-income countries. There are various policy options to expand access to
HCV curative treatment by reducing cost [60]: (1) voluntary licensing (patent holders volun-
tarily licensing generic manufacturing and fixed-dose combinations in defined territories), (2)
differential pricing (patent holders developing different prices based on the countries’ willing-
ness and ability to pay), (3) pre- and post-grant opposition (third parties disputing the validity
of filed patents in countries that have implemented flexibilities of the World Trade Organisa-
tion Agreement on Trade-Related Aspects of Intellectual Property Rights [TRIPS]), or (4) com-
pulsory licenses (countries either importing or locally producing the medications by
implementing TRIPS flexibilities). Thus far, manufacturers of sofosbuvir and daclatasvir have
proposed the use of voluntary licensing for some low- and middle-income countries and differ-
ential pricing for others [61,62]. While this approach proposes a price reduction for 12 weeks
of sofosbuvir from approximately US$84,000 to US$900 for certain countries [62], the produc-
tion price remains substantially less [59]. Since production prices for other DAAs are similar to
sofosbuvir, there is an opportunity to achieve further price reductions in providing HCV treat-
ment [59]. Pre-grant opposition led India’s patent office to reject sofosbuvir’s base compound
Table 1. Properties of second-generation oral anti-HCV agent classes [8,10,59].
NS5B nucleos(t)ide
inhibitor
NS5A inhibitor NS3/4A protease inhibitor NS5B non-
nucleoside inhibitor
Pangenotypic +++ ++ ++ +
Potency +++ ++ ++ +
Potential for price
reductions
+++ +++ +++ -
Major drug interactions ++ Rifampicin could
decrease concentrations
through P-glycoprotein
induction
- +++ Rifampicin, efavirenz, and HIV
protease inhibitors could decrease
concentrations through P450
induction
-
Studied in pregnant
women, paediatrics, and
PWID
+ + + +
Treatment limiting toxicities + + ++ Gastrointestinal distolerance
and anaemia
+
Barrier to resistance +++ ++ ++ +
Agents (bold indicates
licensed, italicised
indicates phase III, and
normal formatting indicates
phase II)
Sofosbuvir (Gilead),
Mericitabine (Roche),
VX-135 (Vertex)
Ledipasvir (Gilead), Ombitasvir
(AbbVie), Daclatasvir (Bristol-
Myers Squibb), Elbasvir (Merck),
GS-5816 (Gilead), ABT-530
(AbbVie), PPI-668 (Presido)
Simeprevir (Janssen),
Paritaprevir/ritonavir (AbbVie),
Asunaprevir (Bristol-Myers Squibb),
Grazoprevir (Merck), Danoprevir
(Roche), Faldaprevir (Boehringer-
Ingelheim), ABT-493 (AbbVie),
Vaniprevir (Merck), GS-9451
(Gilead)
Dasabuvir (AbbVie),
Beclabuvir (Bristol-
Myers Squibb), GS-
9669 (Gilead)
+ indicates low level, ++ indicates moderate level, +++ indicates high level, and - indicates unknown level. US Food and Drug Administration license dates
current as of 31 December 2014.
Abbreviations: NS, nonstructural protein.
doi:10.1371/journal.pmed.1001795.t001
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patent because of patent innovation requirements [63]. Generic production, generic competi-
tion, and price reductions could ensue if the prodrug patent is also rejected [16]. To facilitate
negotiation with generic manufacturers and drive economies of scale, global financing mecha-
nisms and governments will need to procure large quantities of the drugs. In the absence of
price reductions, DAAs may not be a cost-effective treatment option over continued use of
pegylated interferon and ribavirin, particularly for easier to treat genotypes.
Health systems aim to deliver accessible, acceptable, and affordable services. To improve ac-
cessibility and linkage to care, HCV treatment should be integrated into health services that
will provide HCV screening, such as hospitals, primary health facilities, drug-dependence
treatment centres, and HIV/AIDS facilities. Given the absolute shortage of health care provid-
ers, training and supervision from specialised physicians to non-specialised physicians and
nurses to stage patients clinically, initiate treatment, and maintain treatment until cure may be
required. The short duration of HCV treatment with newer DAAs could make directly ob-
served treatment worth considering in some settings. Countries will also need to implement
central procurement and supply chain management systems encompassing antiviral registra-
tion, forecasting, procurement, storage, and distribution to prevent stockouts and reduce cost
[64].
Sustained virological response (SVR), i.e., the absence of HCV RNA 6 months after treat-
ment completion, could be the most critical marker of treatment success [65]. Many low- and
middle-income countries have limited laboratory infrastructure and lack access to HCV RNA
for confirming chronic HCV infection and determining treatment outcome. National laborato-
ry strategic plans are guiding laboratory development as part of health systems strengthening
[66]. Using dried blood spots may help increase access to HCV RNA technology [67]. This ap-
proach could be linked to established systems, such as early infant diagnosis of HIV and antire-
troviral therapy monitoring [68]. High-quality, low-cost, point-of-care RNA tests may also be
available in the future [12,15]. HCV core antigen may be a qualitative alternative to quantita-
tive RNA for measuring treatment response [69]. Health technology assessments by national
panels can ensure rational selection of HCV platforms based on available resources and health
system organisation.
Strategic Information
Countries will have to collect and collate information relevant for developing and modifying
HCV strategies. Integrating HCV into existing surveillance systems, such as population demo-
graphic and health surveys in generalised epidemics and integrated biological and behavioural
surveillance for key populations in all epidemics, is needed to accurately measure HCV burden
and transmission nationally, regionally, and in different subpopulations over time [70,71]. Al-
though limited by biases and generalizability in many countries, routinely collected data can
also provide useful information [72]. For example, blood banks, drug-dependence treatment
centres, and antenatal facilities could provide prevalence estimates. Mortality could be estimat-
ed from civil and vital registration systems, verbal autopsy studies, cancer registries, cremation
and burial services, and health facility data. Morbidity due to cirrhosis and hepatocellular carci-
noma could be estimated from hospitals, health facilities, and hepatitis notification systems.
Since acute HCV infection is largely asymptomatic, it is not routinely diagnosed in health facil-
ities; incidence may need to be estimated by mathematical modelling or routinely screening
representative cohorts for acute HCV infection through sentinel surveillance.
Expanding commonly used tools, such as OneHealth, to include HCV may help in project-
ing the impact and cost-effectiveness of different national strategies [73]. After developing na-
tional HCV strategies, countries will also need to measure progress in implementing them. If
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systematic reporting occurs, cases reported from sites providing HCV screening measured over
national burden estimates can allow programmes to estimate case detection rates. Mandatory
reporting has been used for other infectious diseases to ensure access to care and treatment ser-
vices and might merit consideration for HCV [74]. Linkage to care could be measured by divid-
ing the number of people who enrol into care by the number of people who are diagnosed with
chronic HCV infection. Standardised patient monitoring systems should be used to monitor
treatment response and life-threatening toxicities. Treatment outcomes could focus on five
outcomes after completion of therapy: success, failure, lost-to-follow-up, death, and transferred
Box 1. Key Actions for Creating a Public Health Approach to HCV
Programme development
• Develop political commitment, mobilise resources, reduce costs of medicines and diag-
nostics, and support training programmes for peripheral and community-based
health workers
• Estimate resources and benefits associated with an HCV response
• Develop a global financing mechanism for resource-constrained settings
Prevention
• Screen all donated blood for HCV
• Reduce unnecessary injections
• Implement infection control measures
• Provide clean needles and opiate substitution therapy to PWID
Screening
• Prioritise screening amongst the most affected populations, including those exposed to
unsafe blood, key populations, and people living with HIV/AIDS
• Develop standardised diagnostic algorithms
• Use appropriate mix of health facility—and community-based approaches linked to
HCV care and treatment
Treatment
• Use APRI or FIB-4 for gauging treatment eligibility
• Use effective, well-tolerated, short-duration, and affordable regimens in
national guidelines
• Where possible, integrate treatment into HCV screening sites
Strategic information
• Integrate HCV into surveillance systems
• Measure access to safe blood, infection control practice, and harm reduction coverage
• Use national HCV estimates, case reporting, and treatment cohort analysis to measure
HCV service outcomes across a cascade
Abbreviations: HCV, hepatitis C virus; PWID, persons who inject drugs; APRI, amino-
transferase-to-platelet ratio index; FIB4, Fibrosis-4 score
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in/out. Treatment success rates could be calculated from health registries using cohort analysis
by dividing the number of people who achieve SVR over the number of people who initiate
treatment. These indicators can be measured over a treatment cascade. Existing health indica-
tors, such as access to safe blood, infection control practice, access to sterile syringes for PWID,
and opiate substation therapy coverage, will help gauge success in prevention programming.
Conclusions
Advances in therapeutic options for hepatitis C make improving its detection and treatment
important (Box 1). Global stakeholders, including civil society, countries, donors, and policy
makers, can ensure hepatitis C is a priority on global development agendas. Countries and
partners should begin (1) collecting, analysing, and interpreting data to understand their epi-
demics and develop investment cases, (2) aggressively scaling up robust prevention strategies
based on local transmission dynamics, and (3) providing systematic screening and treatment
services initially prioritising those most in need. The major limiting steps are the high cost of
treatment and the absence of affordable and reliable diagnostic tests; similar conundrums were
faced 15 years ago by the HIV/AIDS community. The success of this community in driving
major price reductions for lifelong antiretroviral therapy and achieving universal treatment ac-
cess demonstrates the feasibility of reducing the cost of short-course HCV treatment and rap-
idly expanding its access as part of a comprehensive viral hepatitis response [75].
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